- Conditions
- Cholestasis, Total Parenteral Nutrition-induced Cholestasis
- Interventions
- Omegaven
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- Up to 18 Years
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 197
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alagille Syndrome, Cholestasis, Biliary Atresia
- Interventions
- magnesium gluconate, magnesium sulfate
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Liver Transplantation, Hepatitis, Cholestasis, Carcinoma, Hepatocellular
- Interventions
- IDN-6556, Placebo
- Drug
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Liver and Intrahepatic Bile Duct Disorder
- Interventions
- Bupivacaine, Fentanyl, Hydromorphone Hydrochloride, Implanted Medical Device, Liposomal Bupivacaine, Questionnaire
- Drug · Device · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- LUM001
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- La Jolla, California • Sacramento, California • Miami, Florida + 10 more
- Conditions
- Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
- Interventions
- Not listed
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2029
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Clinic visit, Baseline visit
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Elafibranor, Placebo
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 20
- States / cities
- Coronado, California • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Parenteral Nutrition Associated Liver Disease, Short Bowel Syndrome, Gastrointestinal Disease
- Interventions
- Omegaven®
- Drug
- Lead sponsor
- Mark Puder
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cholestasis of Parenteral Nutrition
- Interventions
- Smoflipid 20% Lipid Emulsion for Injection, Intralipid, 20% Intravenous Emulsion
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Not listed
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Obeticholic Acid (OCA), Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 15
- States / cities
- Sacramento, California • San Diego, California • Aurora, Colorado + 11 more
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Pancreatic Cancer, Quality of Life, Small Intestine Cancer
- Interventions
- bowel obstruction management, quality-of-life assessment
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Hepatic Pruritus, Cholestatic Liver Disease, Primary Biliary Cholangitis, Cholestasis, Primary Sclerosing Cholangitis
- Interventions
- Nemolizumab-ilto
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 9
- States / cities
- Pasadena, California • Miami, Florida • Marietta, Georgia + 5 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Seladelpar 10 mg, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 43
- States / cities
- Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more
- Conditions
- Choledocholithiasis, Biliary Obstruction
- Interventions
- Cholangioscopy, Spyglass DS Cholangioscope
- Procedure · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Total Parenteral Nutrition-Induced Cholestasis
- Interventions
- Omegaven
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Primary Biliary Cholangitis
- Interventions
- EDP-305 1 mg, EDP-305 2.5 mg, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 40
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Coronado, California + 28 more
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Biliary Tract Neoplasms, Biliary Duct Obstruction, Unresectable Pancreatic Cancer, Periampullary Cancer, Periampullary Carcinoma Non-Resectable
- Interventions
- Endoscopic Ultrasound Guided Biliary Drainage, ERCP
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
- Interventions
- SMOFlipid® (lipid injectable emulsion)
- Drug
- Lead sponsor
- Fresenius Kabi
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 3 more
- Conditions
- Alagille Syndrome
- Interventions
- LUM001, Placebo
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- Distal Bile Duct Obstruction
- Interventions
- Covered Self-expanding metal biliary stents (C-SEMS), Uncovered Self-expanding metal biliary stents (U-SEMS)
- Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Alagille Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cholangitis, Sclerosing, Liver Cirrhosis, Biliary
- Interventions
- budesonide
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota